| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Articles |
Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267
Abstract
Eukaryotic cells have evolved a mechanism that delays the progression of mitosis until condensed chromosomes are properly positioned on the mitotic spindle. To understand the molecular basis of such monitoring mechanism in human cells, we have been studying genes that regulate the mitotic checkpoint. Our early studies have led to the cloning of a full-length cDNA encoding MAD3-like protein (also termed BUBR1/MAD3/SSK1). Dot blot analyses show that BUBR1 mRNA is expressed in tissues with a high mitotic index but not in differentiated tissues. Western blot analyses show that in asynchronous cells, BUBR1 protein primarily exhibits a molecular mass of 120 kDa, and its expression is detected in most cell lines examined. In addition, BUBR1 is present during various stages of the cell cycle. As cells enter later S and G2, BUBR1 levels are increased significantly. Nocodazole-arrested mitotic cells obtained by mechanical shake-off contain BUBR1 antigen with a slower mobility on denaturing SDS gels. Phosphatase treatment restores the slowly migrating band to the interphase state, indicating that the slow mobility of the BUBR1 antigen is attributable to phosphorylation. Furthermore, purified recombinant His6-BUBR1 is capable of autophosphorylation. Our studies indicate that BUBR1 phosphorylation status is regulated during spindle disruption. Considering its strong homology to BUB1 protein kinase, BUBR1 may also play an important role in mitotic checkpoint control by phosphorylation of a critical cellular component(s) of the mitotic checkpoint pathway.
This article has been cited by other articles:
![]() |
V. Appierto, P. Tiberio, E. Cavadini, P. Casalini, G. Cappelletti, and F. Formelli Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity Mol. Cancer Ther., December 1, 2009; 8(12): 3360 - 3368. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Rao, H. Y. Yamada, Y. Yao, and W. Dai Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice Carcinogenesis, September 1, 2009; 30(9): 1469 - 1474. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. W. Chan, K. F. On, W. M. Chan, W. Wong, H. O. Siu, P. M. Hau, and R. Y. C. Poon The Kinetics of p53 Activation Versus Cyclin E Accumulation Underlies the Relationship between the Spindle-assembly Checkpoint and the Postmitotic Checkpoint J. Biol. Chem., June 6, 2008; 283(23): 15716 - 15723. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Aneja, M. Liu, C. Yates, J. Gao, X. Dong, B. Zhou, S. N. Vangapandu, J. Zhou, and H. C. Joshi Multidrug Resistance-Associated Protein-Overexpressing Teniposide-Resistant Human Lymphomas Undergo Apoptosis by a Tubulin-Binding Agent Cancer Res., March 1, 2008; 68(5): 1495 - 1503. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Greene, G. Campiani, M. Lawler, D. C. Williams, and D. M. Zisterer BubR1 Is Required for a Sustained Mitotic Spindle Checkpoint Arrest in Human Cancer Cells Treated with Tubulin-Targeting Pyrrolo-1,5-Benzoxazepines Mol. Pharmacol., February 1, 2008; 73(2): 419 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsumura, F. Toyoshima, and E. Nishida Polo-like Kinase 1 Facilitates Chromosome Alignment during Prometaphase through BubR1 J. Biol. Chem., May 18, 2007; 282(20): 15217 - 15227. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Myslinski, M.-A. Gerard, A. Krol, and P. Carbon Transcription of the human cell cycle regulated BUB1B gene requires hStaf/ZNF143 Nucleic Acids Res., May 11, 2007; 35(10): 3453 - 3464. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Tao, V. J. South, R. E. Diehl, J. P. Davide, L. Sepp-Lorenzino, M. E. Fraley, K. L. Arrington, and R. B. Lobell An Inhibitor of the Kinesin Spindle Protein Activates the Intrinsic Apoptotic Pathway Independently of p53 and De Novo Protein Synthesis Mol. Cell. Biol., January 15, 2007; 27(2): 689 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guo, G. Wu, J. L. Chin, G. Bauman, M. Moussa, F. Wang, N. M. Greenberg, S. S. Taylor, and J. W. Xuan Bub1 Up-Regulation and Hyperphosphorylation Promote Malignant Transformation in SV40 Tag-Induced Transgenic Mouse Models Mol. Cancer Res., December 1, 2006; 4(12): 957 - 969. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kim, K. Murphy, F. Liu, S. E. Parker, M. L. Dowling, W. Baff, and G. D. Kao Caspase-Mediated Specific Cleavage of BubR1 Is a Determinant of Mitotic Progression Mol. Cell. Biol., November 1, 2005; 25(21): 9232 - 9248. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Oikawa, M. Okuda, Z. Ma, R. Goorha, H. Tsujimoto, H. Inokuma, and K. Fukasawa Transcriptional Control of BubR1 by p53 and Suppression of Centrosome Amplification by BubR1 Mol. Cell. Biol., May 15, 2005; 25(10): 4046 - 4061. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, T. Liu, Y. Fang, S. Xie, X. Huang, R. Mahmood, G. Ramaswamy, K. M. Sakamoto, Z. Darzynkiewicz, M. Xu, et al. BUBR1 deficiency results in abnormal megakaryopoiesis Blood, February 15, 2004; 103(4): 1278 - 1285. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Dai, Q. Wang, T. Liu, M. Swamy, Y. Fang, S. Xie, R. Mahmood, Y.-M. Yang, M. Xu, and C. V. Rao Slippage of Mitotic Arrest and Enhanced Tumor Development in Mice with BubR1 Haploinsufficiency Cancer Res., January 15, 2004; 64(2): 440 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Baek, H.-J. Shin, J.-K. Yoo, J.-H. Cho, Y.-H. Choi, Y.-C. Sung, F. McKeon, and C.-W. Lee p53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest J. Leukoc. Biol., June 1, 2003; 73(6): 850 - 861. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |